http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102947325-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c564991ae13d25b7772e76de8d0160e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0781 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2011-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68de2e6eb8753b346dc7ca38d0b6a204 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e79e0bf7f41ccfc63afad69ecb9cf60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60c3661e2747447646670727c026027a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6935469b980a350f2e569820f6a8aa0f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c9000ac63a51d59e17fb7d98b40bfc4 |
| publicationDate | 2015-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102947325-B |
| titleOfInvention | Cdca5 peptides and vaccines including the same |
| abstract | Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor. |
| priorityDate | 2010-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 295.